Compare PK & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PK | ZLAB |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2014 | 2017 |
| Metric | PK | ZLAB |
|---|---|---|
| Price | $11.04 | $19.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $11.22 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 4.2M | 626.3K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.82% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $2,791,000,000.00 | $460,156,000.00 |
| Revenue This Year | $2.40 | $9.75 |
| Revenue Next Year | $2.76 | $26.03 |
| P/E Ratio | $226.30 | ★ N/A |
| Revenue Growth | 2.35 | ★ 15.33 |
| 52 Week Low | $9.84 | $15.96 |
| 52 Week High | $12.39 | $44.34 |
| Indicator | PK | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 42.28 |
| Support Level | $10.85 | $19.51 |
| Resistance Level | $11.79 | $19.64 |
| Average True Range (ATR) | 0.34 | 0.99 |
| MACD | -0.03 | -0.47 |
| Stochastic Oscillator | 12.70 | 22.01 |
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 21,042 rooms across 33 hotels in the United States. Park also has interests through joint ventures in another 1,712 rooms in two US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.